fda glp-1 warning news september 2025 Alarming rise in weight loss drug overdoses FDA Issues Warning Letters to

Pharmacokinetic studies in rats demonstrated an oral bioavailability of 38.4%, with a mean Cmax of 2,252 ng/mL and terminal elimination half-lives of 3.80 1.10 hours (IV) and 6.90 1.20 hours (oral) (Awosemo et al., 2021)

And how to think about them if your goal is wellness and longevity, not shortcuts

In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]

It is also approved to reduce the risk of major adverse cardiovascular events in adults who have cardiovascular disease and are either overweight or have obesity

You deserve to feel amazing in your bodyand Im here to help you get there